Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity | Synapse

November 19, 2021Open Access

Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity

HCHyeree ChoiThe Wistar Institute MHMichelle HoThe Wistar Institute OAOpeyemi S. AdenijiCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

testing utilizing ovarian cancer humanized mouse model showed a drastic reduction in tumor volume. Together, we developed novel antibodies that augment anti-tumor immunity through interference with Siglec-9-mediated immunosuppression.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Choi et al. (Fri,) studied this question.

synapsesocial.com/papers/6a0514746c3d07813971bdbd https://doi.org/https://doi.org/10.3389/fonc.2021.778989

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Siglec-9, a Novel Sialic Acid Binding Member of the Immunoglobulin Superfamily Expressed Broadly on Human Blood Leukocytes2000 · 236 citations
2Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial2019 · 322 citations
3Decreased erythrocyte binding of Siglec-9 increases neutrophil activation in sickle cell disease2019 · 19 citations
4Purification, crystallization and preliminary crystallographic study of neuraminidase from Vibrio cholerae and Salmonella typhimurium LT21992 · 33 citations
5Siglecs as targets for therapy in immune-cell-mediated disease2009 · 186 citations